Chikungunya vaccine candidate progresses in Phase 1 study
by Press Release from Outbreak News Today on (#40ZNE)
Valneva SE, a commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya. The Company has now commenced the second stage of its Phase 1 study. A first group of study participants is now being re-vaccinated. This re-vaccination will act as ["]
The post Chikungunya vaccine candidate progresses in Phase 1 study appeared first on Outbreak News Today.